Test on Ovarian Stimulation in IVF

Question 1: The process of atresia, where most follicles in a cohort die in a typical natural cycle, is considered a pathological event.

A. Ano

B. Ne

Explanation: Atresia is the default fate for most follicles in a cohort and is considered a design, not a pathology, in a typical natural cycle. For example, if 15 follicles enter a cohort, 14 dying is normal.

Question 2: Based on the provided physiology, which statements accurately describe the FSH window and threshold concepts in the context of ovarian follicular dynamics?

A. The FSH window refers to how long FSH stays above a specific sensitivity level for a cohort of follicles.

B. Follicles with a higher FSH threshold are generally rescued first during cyclic recruitment in a natural cycle.

C. Ovarian stimulation aims to widen the FSH window, allowing more follicles to overcome their threshold and develop.

D. In a natural cycle, the FSH window typically closes as the dominant follicle suppresses FSH production.

Explanation: The FSH window is defined as how long FSH stays above the threshold for the cohort of follicles. Ovarian stimulation's primary goal is to widen this window, thereby rescuing more follicles from atresia by keeping them above their individual FSH sensitivity threshold for a longer period. In a natural cycle, the FSH window closes as FSH falls due to the dominant follicle's secretions, leading to atresia for other follicles. Follicles with a *lower* FSH threshold are rescued first, not those with a higher threshold.

Question 3: The long agonist protocol is associated with a higher risk of Ovarian Hyperstimulation Syndrome (OHSS).

A. Ano

B. Ne

Explanation: The study materials explicitly state 'Higher OHSS risk' as a disadvantage of the long agonist protocol.

Question 4: For embryologists, recording the use of originator versus biosimilar follitropin alfa is considered a crucial diagnostic variable for interpreting cycle outcomes.

A. Ano

B. Ne

Explanation: The study materials state that for embryologists, recording originator versus biosimilar is administrative, not interpretive, meaning it is not a diagnostic variable.

Question 5: According to the provided study materials, which of the following are considered appropriate options for luteal support in a fresh transfer cycle?

A. Oral dydrogesterone

B. Vaginal progesterone

C. hCG support, despite its historical use

D. IM progesterone alone, as it's the predominant US practice

Explanation: The study materials list Vaginal progesterone as 'Standard' and Oral dydrogesterone as 'Increasingly common' for luteal support. hCG support is also mentioned as an original method that 'Works' to sustain the corpus luteum, even though it 'increases OHSS risk substantially' and is 'Now rarely used in fresh transfer cycles.' The information about 'US practice predominantly IM' and two-route regimens (vaginal + IM) is specifically for 'Programmed FET (no CL)' where replacement is needed, not for fresh cycles where 'vaginal P sufficient' for supplementation.